Latest News

  • 11th September 2024

    ARECOR PRESENTS POSITIVE DATA FROM PHASE I CLINICAL TRIAL OF AT278 IN LATE-BREAKING ORAL PRESENTATION AT EASD 2024

  • 3rd September 2024

    ARECOR ANNOUNCES ORAL PRESENTATION OF POSITIVE AT278 PHASE 1 CLINICAL DATA AT THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES 2024

  • 21st May 2024

    ARECOR TO HOST COMPANY AND KOL WEBINAR TODAY TO DISCUSS CLINICAL TRIAL RESULTS FOR ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN AT278 DEMONSTRATING SUPERIORITY IN PEOPLE WITH TYPE 2 DIABETES

News

Reset
  • 11/09/2024

    ARECOR PRESENTS POSITIVE DATA FROM PHASE I CLINICAL TRIAL OF AT278 IN LATE-BREAKING ORAL PRESENTATION AT EASD 2024

  • 03/09/2024

    ARECOR ANNOUNCES ORAL PRESENTATION OF POSITIVE AT278 PHASE 1 CLINICAL DATA AT THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES 2024

  • 21/05/2024

    ARECOR TO HOST COMPANY AND KOL WEBINAR TODAY TO DISCUSS CLINICAL TRIAL RESULTS FOR ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN AT278 DEMONSTRATING SUPERIORITY IN PEOPLE WITH TYPE 2 DIABETES

  • 20/05/2024

    AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN DEMONSTRATES SUPERIORITY IN PHASE I CLINICAL TRIAL IN OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2 DIABETES

  • 09/05/2024

    ARECOR AND MEDTRONIC DIABETES ESTABLISH COLLABORATION TO DEVELOP A NOVEL THERMOSTABLE INSULIN FOR IMPLANTABLE PUMP DELIVERY

  • 12/03/2024

    ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY

  • 29/02/2024

    ARECOR ANNOUNCES LAUNCH OF OGLUO® IN THE NETHERLANDS

  • 23/01/2024

    ARECOR ANNOUNCES UPDATE ON INBRX-101

  • 18/01/2024

    ARECOR GRANTED KEY EUROPEAN PATENT EXTENDING PROTECTION FOR INSULIN PRODUCTS, AT278 AND AT247

  • 08/01/2024

    ARECOR ANNOUNCES EXPANSION OF EXISTING SPECIALTY HOSPITAL FORMULATION COLLABORATION

  • 03/01/2024

    ARECOR APPOINTS DR HELEN PARRIS AS SVP, COMMERCIAL & GENERAL MANAGER OF TETRIS PHARMA LTD.